Shares of other companies:
May 1, 2024 Inflation Persistence: No Fed Rate Cuts in Sight
April 29, 2024 Tesla, Baidu Join Forces for Self-Driving Tech in China
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
3M Stock: Dividend Likely Cut In Half
May 1, 2024
Amazon Q1 Review: Best Of Big Tech Bunch
April 30, 2024
Tesla: The Thesis Is Stronger Than Ever
April 30, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
PTGX Stock News and Mentions of Protagonist Therapeutics, Inc. Stocktwits
Updated: May 2, 2024 (11:06)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Protagonist Therapeutics Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Protagonist Therapeutics, Inc. (PTGX).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Protagonist Therapeutics stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Protagonist Therapeutics, Inc. (PTGX)
April 5, 2024 (16:00) / "Zacks Commentary" (by Zacks Equity Research)
All You Need to Know About Protagonist Therapeutics ( PTGX ) Rating Upgrade to Buy
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
In Article Trend: Somewhat-Bullish
March 25, 2024 (10:05) / "GlobeNewswire" (by ProKidney)
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies ...
In Article Trend: Neutral
March 18, 2024 (13:55) / "Zacks Commentary" (by Zacks Equity Research)
Wall Street Analysts Think Protagonist Therapeutics ( PTGX ) Could Surge 48.38%: Read This Before Placing a Bet
The consensus price target hints at a 48.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
In Article Trend: Somewhat-Bullish
March 15, 2024 (10:13) / "Zacks Commentary" (by Tirthankar Chakraborty)
4 Stocks to Buy for Attractive Earnings Acceleration
Invest in stocks such as Protagonist Therapeutics (PTGX), Evolus (EOLS), Western Digital (WDC), and Phunware (PHUN) as of now for superb earnings acceleration.
In Article Trend: Bullish
March 9, 2024 (17:00) / "PR Newswire" (by Johnson & Johnson)
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in ... PR ...
In Article Trend: Neutral
March 4, 2024 (12:05) / "Zacks Commentary" (by Tirthankar Chakraborty)
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN), Western Digital (WDC) and Phunware (PHUN).
In Article Trend: Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website